Literature DB >> 25263953

Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Rose Nabatanzi1, Lois Bayigga2, Isaac Ssinabulya3, Agnes Kiragga4, Andrew Kambugu5, Joseph Olobo6, Moses Joloba7, Moses R Kamya8, Harriet Mayanja-Kizza9, Damalie Nakanjako10.   

Abstract

BACKGROUND: CD4 counts guide antiretroviral therapy (ART) initiation and prophylaxis for opportunistic infections. It is unclear whether normal CD4 counts translate to normalized immune responses among ART-treated adults. We compared antigen-specific CD4 T-cell immune responses among ART-treated adults with CD4≥500cells/μl, optimal immune responders (O-IR), and their age-matched healthy HIV-negative counterparts.
METHODS: In a sample-based case-control study, cryopreserved peripheral blood mononuclear cells from 15 O-IR after 7 years of ART and 15 healthy controls, were analyzed for CD4+ T-cell proliferation using CFSE dye and cytokine production.
RESULTS: CD4 T-cell proliferation, upon stimulation with PPD and pneumococcal polysaccharide antigen, was lower among O-IR relative to HIV-negative controls; p=0.016 and p=0.016 respectively. CD4 T-cell production of IL-2 was lower among O-IR relative to HIV-negative control p=0.002. CD4 T-cell proliferation upon stimulation with SEB and CMV antigens was similar among O-IR and HIV-negative controls p=0.971 and p=0.480, respectively, and so was IL-4 and IFN γ production; p=0.528 and p=0.892, respectively.
CONCLUSION: Seven years of suppressive ART caused partial CD4 T-cell function recovery in an African HIV treatment cohort, despite restoration of CD4 T-cell counts to levels≥500cells/μl. The role innate immunity in the recovery of immune function during long-term ART should be investigated to guide decisions on continued prophylaxis against opportunistic infections.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ART; CD4 T-cell proliferation; Cytokine production; Immune recovery; Sub-Saharan Africa; Uganda

Mesh:

Substances:

Year:  2014        PMID: 25263953      PMCID: PMC4537512          DOI: 10.1016/j.imlet.2014.09.016

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  31 in total

1.  Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Authors:  Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Authors:  Christine A Jansen; Iris M De Cuyper; Radjin Steingrover; Suzanne Jurriaans; Sanjay U C Sankatsing; Jan M Prins; Joep M A Lange; Debbie van Baarle; Frank Miedema
Journal:  AIDS       Date:  2005-07-22       Impact factor: 4.177

3.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

Authors:  B Ledergerber; A Mocroft; P Reiss; H Furrer; O Kirk; M Bickel; C Uberti-Foppa; C Pradier; A D'Arminio Monforte; M M Schneider; J D Lundgren
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

Review 4.  Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection.

Authors:  Pierre Corbeau; Jacques Reynes
Journal:  Blood       Date:  2011-03-14       Impact factor: 22.113

5.  Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Authors:  Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

6.  Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

Authors:  Hernan Valdez; Elizabeth Connick; Kimberly Y Smith; Michael M Lederman; Ronald J Bosch; Ryung S Kim; Marty St Clair; Daniel R Kuritzkes; Harold Kessler; Lawrence Fox; Michelle Blanchard-Vargas; Alan Landay
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

7.  Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Authors:  Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

8.  Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults.

Authors:  Sarah J Glennie; Enoch Sepako; David Mzinza; Visopo Harawa; David J C Miles; Kondwani C Jambo; Stephen B Gordon; Neil A Williams; Robert S Heyderman
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

9.  High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.

Authors:  Lois Bayigga; Rose Nabatanzi; Prossy Naluyima Sekiziyivu; Harriet Mayanja-Kizza; Moses R Kamya; Andrew Kambugu; Joseph Olobo; Agnes Kiragga; Sam Kirimunda; Moses Joloba; Damalie Nakanjako
Journal:  BMC Immunol       Date:  2014-01-31       Impact factor: 3.615

10.  Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

Authors:  Damalie Nakanjako; Agnes Kiragga; Fowzia Ibrahim; Barbara Castelnuovo; Moses R Kamya; Philippa J Easterbrook
Journal:  AIDS Res Ther       Date:  2008-10-28       Impact factor: 2.250

View more
  4 in total

1.  Innate lymphoid cell dysfunction during long-term suppressive antiretroviral therapy in an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Stephen Cose; Glenda Canderan; Sarah Rowland Jones; Moses Joloba; Damalie Nakanjako
Journal:  BMC Immunol       Date:  2021-08-26       Impact factor: 3.615

2.  Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Stephen Cose; Sarah Rowland-Jones; Glenda Canderan; Moses Joloba; Damalie Nakanjako
Journal:  Clin Immunol       Date:  2019-02-26       Impact factor: 3.969

3.  Elevated KIR expression and diminished intensity of CD7 on NK cell subsets among treatment naïve HIV infected Ethiopians.

Authors:  Henok Andualem; Mulualem Lemma; Amare Keflie; Meseret Workeneh; Birhanu Ayelign; Yayehyirad Tassachew; Lidya Hailu; Alene Geteneh; Adane Mihret; Martha Zewdie; Rawleigh Howe
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 4.  Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells.

Authors:  Rose Nabatanzi; Stephen Cose; Moses Joloba; Sarah Rowland Jones; Damalie Nakanjako
Journal:  AIDS Res Ther       Date:  2018-03-15       Impact factor: 2.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.